Heterogeneous nuclear ribonucleoproteins (HNRNPs) are crucial members in the pathogenesis and progression of numerous cancers. However, the expression pattern and clinical significance of HNRNPs in breast carcinoma (BC) remain to be investigated. In the present study, bioinformatic analysis identified HNRNPAB as the only commonly upregulated HNRNP in BC. Elevated expression of HNRNPAB was positively associated with more aggressive diseases and poorer survival rates in BC. Pathway analysis revealed that HNRNPAB coexpressed genes were enriched in the pathway of G2/M phase transition, and the expression level of HNRNPAB was strongly correlated with those of CCNB1, CDK1, CDC25A, and CDC25C. Experiments in vitro demonstrated that HNRNPAB knockdown suppressed cell proliferation and blocked the G2/M phase transition in BC. Taken together, this study provides the initial evidence that HNRNPAB may be employed as an innovative therapeutic target as well as a prognostic biomarker in BC patients.

中文翻译：

---

HNRNPAB在乳腺癌中的预后价值及其功能的挖掘。

异质核糖核蛋白（HNRNP）是众多癌症的发病机理和进展中的关键成员。然而，HNRNPs在乳腺癌（BC）中的表达模式和临床意义仍有待研究。在本研究中，生物信息学分析确定HNRNPAB是BC中唯一普遍上调的HNRNP。HNRNPAB的高表达与更具侵略性的疾病和较差的BC生存率呈正相关。途径分析表明，HNRNPAB共表达的基因在G2 / M相变途径中富集，并且HNRNPAB的表达水平与CCNB1，CDK1，CDC25A和CDC25C的表达高度相关。体外实验证明HNRNPAB组合体抑制了细胞增殖并阻止了BC中G2 / M的相变。两者合计，这项研究提供了初步的证据表明HNRNPAB可以作为BC患者的创新治疗靶点和预后生物标志物。